CAMP4 THERAPEUTICS CORP
CAMPNASDAQTrading Snapshot
- Day Range
- $3.89 – $3.95
- 52-Week Range
- $2.85 – $7.75
- Volume
- $3.72B
- Avg Volume
- $4.90B
- Shares Outstanding
- 21.2M
- Next Earnings
- Oct 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $2M
- P/E Ratio
- -1.7
- P/S Ratio
- 19.4x
- EPS (TTM)
- $-1.85
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +166.1%
Why Investors Own CAMP
- ✓High-growth profile — revenue up +11.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 66% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CAMP4 THERAPEUTICS CORP
CAMP
StockOtter · stockotter.spaceAbout CAMP4 THERAPEUTICS CORP
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
CAMP4 Therapeutics (NASDAQ: CAMP) said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first h
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4's recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics desi
CAMP4 to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Québec
Vancouver, British Columbia – TheNewswire - August 31, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) (“ Canadian GoldCamps ” or the “ Company ”) announces that, further to its news release dated Aug